10/31/2006 | BT | Market Commentary: Alnylam, CytRx gain with Sirna; Antigenics gains; Viragen sinks; ZymoGenetics off ahead of results
|
10/30/2006 | BT | Market Commentary: Sirna soars after hours on Merck $1.1 billion buyout; Emisphere plunges 24%; Point better by 19%
|
9/8/2006 | BT | Market Commentary: Discovery Labs spikes on buyout buzz; Cell Genesys loses 5% on bought deal; Oscient buffeted
|
8/10/2006 | BT | Sirna macular degeneration study shows 100% visual acuity stabilization
|
6/23/2006 | BT | European Patent Office accepts Sirna's objections, limits Kreutzer-Limmer RNA patent claims
|
6/8/2006 | BT | Market Commentary: AtheroGenics drops; Nastech up; Novavax, BioCryst decline; Sirna slides; Acadia off; XenoPort drops
|
5/30/2006 | BT | Sirna Therapeutics greenshoe exercised, raising stock sale to $52 million
|
5/24/2006 | BT | Market Commentary: Sirna, Minrad, AngioDynamics follow-on deals get off; bird flu vaccine names continue to climb
|
5/24/2006 | BT | New Issue: Sirna raises $45 million in upsized follow-on of 9 million shares at $5 each, versus $5.13 close
|
5/23/2006 | BT | Sirna follow-on offering remains at 8 million shares, secondary for 2 million shares withdrawn
|
5/23/2006 | BT | Market Commentary: Sirna slides 8% ahead of reduced deal; Auxilium gains; Alnylam off; bird flu names up after hours
|
5/19/2006 | BT | Market Commentary: Illumina gains after spot sale; Neurocrine, DOV mixed; Pozen pounded; Alkermes dips, settles higher
|
5/15/2006 | BT | Sirna plans follow-on offering of 8 million shares, another 2 million shares to be sold in secondary
|
5/15/2006 | BT | Market Commentary: BioMimetic goes south; Sirna off on new deal; Cambridge rockets on buyout; Threshold extends fall
|
5/10/2006 | BT | Sirna Therapeutics signs license for microRNA technology from UMass Medical School
|
5/4/2006 | BT | Sirna, GlaxoSmithKline to pursue RNAi-based therapeutics
|
5/1/2006 | BT | Market Commentary: Teva shares, convertibles gain on Zocor ruling; NeoPharm off amid downsizing; Alnylam, Idenix drop
|
4/5/2006 | BT | Market Commentary: Allergan rolls out $700 million note; Discovery falls on FDA request for more data; Human Genome up
|
4/3/2006 | BT | GlaxoSmithKline, Sirna form alliance for RNAi-based respiratory therapies
|
4/3/2006 | BT | Sirna granted first broad siRNA U.S. patent for a gene target
|
3/28/2006 | BT | Protiva files suits against Inex, Sirna to protect development of delivery technologies
|
2/23/2006 | BT | Market Commentary: Kos crashes on results, warning; GTC garroted by E.U. rejection; Nastech higher; Biovail mixed
|
2/3/2006 | BT | Market Commentary: DOV rises; ImmunoGen tumbles; OccuLogix, TLC-Vision plunge; Sirna spikes; CryoCor crumbles
|
1/24/2006 | BT | Sirna gets patent covering large-scale synthesis of RNAi-based therapeutics
|
12/21/2005 | BT | Sirna says it will advance Sirna-AV34 to clinical testing for hepatitis C
|
11/23/2005 | BTCV | Sirna Therapeutics files $75 million shelf
|
10/19/2005 | BT | Sirna's macular degeneration treatment helps vision, phase I trial finds
|
9/8/2005 | BT | Market Commentary: Myogen, NPS float follow-ons; Nektar halted during FDA panel; Sepracor up in face of generic filing
|
7/7/2005 | BTPP | New Issue: Sirna Therapeutics releases additional details on $28.01 million private placement
|
7/6/2005 | PP | Market Commentary: SmarTire raises $190 million in private placements; oil surges over $61 a barrel, fueling energy offerings
|
7/5/2005 | BT | Market Commentary: Voyager plans IPO; Able Labs plunges; Mylan Labs launch seen; Boston Scientific up, J&J lower
|
7/5/2005 | PP | Market Commentary: Volume picks up following holiday weekend; Sirna Therapeutics raises $28 million
|
7/5/2005 | BTPP | New Issue: Sirna Therapeutics raises $28 million in private placement of stock
|